Ignite Creation Date:
2024-05-05 @ 11:33 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00079742
Status:
COMPLETED
Last Update Posted:
2008-06-09
First Post:
2004-03-11
Brief Title:
A Study to Evaluate Nutropin AQ for the Treatment of Growth Restriction in Children With Cystic Fibrosis
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
A Phase II Multicenter Randomized Controlled Open-Label Study of the Safety and Efficacy of Nutropin AQ Somatropin DNA Origin Injection for the Treatment of Growth Restriction in Children With Cystic Fibrosis
Status:
COMPLETED
Status Verified Date:
2008-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase II multicenter randomized controlled open-label trial of the safety and efficacy of Nutropin AQ administered subcutaneously SC daily in prepubertal children with CF and growth restriction
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None